蜂蜜处理黄芪是基数的剂型黄芪以提高免疫活性的中药加工方法与蜂蜜混合。蜂蜜加工黄芪多糖(HP-APS)的这种药理活性可能是由于蜂蜜烘烤过程中的结构变化。此前,我们已经制备并表征了HP-APS,并初步发现了它的抗炎作用。然而,HP-APS 的药效学活性是否诱导肿瘤细胞凋亡以及导致免疫原性死亡 (ICD) 的机制尚未阐明。在这里,A549、MC38 和 B16 细胞分别用于评估细胞活力、细胞凋亡和细胞周期。细胞免疫原性细胞死亡相关分子钙网蛋白 (CRT)、热休克蛋白 (HSP)70、主要组织相容性复合物 I (MHC-I)、通过流式细胞术测定共刺激分子CD80/CD86。还检测到细胞外 ATP 释放。B16-OVA 和 MC38-OVA 细胞用 HP-APS 处理并与 CD3+T 细胞的 OT1 小鼠共培养以评估增殖,在小鼠模型中,并建立带有 B16 细胞的 C57BL/B6 小鼠模型以评估HP-APS 调节免疫活性在体内。我们的研究结果表明,HP-APS对肿瘤细胞增殖具有抑制作用,可诱导肿瘤细胞凋亡,阻止细胞在细胞周期中从G1期向S期转化。此外,HP-APS 可有效增加 HSP70、CRT、MHC-I、CD86、CD80 和 ATP 释放的表达。T细胞增殖指数明显提高。OT1小鼠CD3细胞增殖从第4代到第5代显着增加。此外,结果还表明,HP-APS 可以通过增加肿瘤组织中的免疫细胞浸润来抑制肿瘤生长。在HP-APS治疗的小鼠黑色素瘤模型中,肿瘤重量和体积显着减小,黑色素瘤的生长受到抑制。CD8 +T 显着增加。小鼠脾脏中CD4 + T和CD8 + T细胞数量的比例也显着增加,但低于单独单独使用PD-1治疗。总之,这些发现表明HP-APS具有抗肿瘤作用,其潜在机制可能与免疫原性细胞死亡相关分子的表达和免疫细胞的免疫调节作用有关。
"点击查看英文标题和摘要"
Evidence of immunogenic cancer cell death induced by honey-processed Astragalus polysaccharides in vitro and in vivo
Honey-processed Astragalus is a dosage form of Radix Astragalus mixed with honey by a traditional Chinese medicine processing method which improves immune activity. This pharmacological activity of honey-processed Astragalus polysaccharide (HP-APS) might be due to structural changes during the honey roasting process. Previously, we have prepared and characterized HP-APS and preliminarily found its anti-inflammatory effects. However, whether the pharmacodynamic activity of HP-APS induces tumor cell apoptosis and the mechanisms responsible for the immunogenic death (ICD) have not been elucidated. Here, A549, MC38 and B16 cells were used to evaluate the cells viability, apoptosis and cell cycles, respectively. Cellular immunogenic cell death-related molecules calreticulin (CRT), Heat Shock Proteins (HSP)70, major histocompatibility complex I (MHC-I), and co-stimulator molecules CD80/CD86 were determined by flow cytometry. The extracellular ATP release was also detected. B16-OVA and MC38-OVA cells were treated with HP-APS and co-cultivated with OT1 mouse of CD3+T cells for assessment of proliferation, in mice model, and the establishment of C57BL/B6 mouse model bearing B16 cells for assessment of HP-APS the regulation of immune activity in vivo. Our results showed that HP-APS has an inhibitory effect on tumor cell proliferation, which induces tumor cell apoptosis, preventing cells-transforming from G1 phase to S phase in cell cycles. Furthermore, HP-APS could effectively increase the expression of HSP70, CRT, MHC-I, CD86, CD80 and ATP release. T cell proliferation index is significantly improved. CD3 cell proliferation in OT1 mice was significantly increased from the 4th generation to the 5th generation. Moreover, the results have also shown that HP-APS could inhibit tumor growth by increasing immune cell infiltration in the tumor tissues. In the mouse melanoma model with HP-APS treatment, the tumor weight and volume were significantly reduced, and the growth of melanoma was inhibited. CD8+ T is significantly increased. The ratio of CD4+ T and CD8+ T cells numbers are also significantly increased in mouse spleen, but it is less than PD-1 alone treatment separately. Altogether, these findings suggest that HP-APS exerts anti-tumor effects, and that its underlying mechanisms might be associated with the expression of immunogenicity cell death related molecules and the immunomodulatory effects of immune cells.